Considering the mutant allele depth of the MLH1 gene in the tumour of the LS-CRC patient (II.2, 73%) is about two fold higher than in the blood (germline, 38%), a second hit in the MLH-1 allele is likely to have occurred, thereby contributing to CRC progression. The gene discussed is MLH1; the disease is neoplasm.